TGF-β1 and CXCL12 modulate proliferation and chemotherapy sensitivity of acute myeloid leukemia cells co-cultured with multipotent mesenchymal stromal cells

References

• Schepers K, Campbell TB, Passegué E. Normal and leukemic stem cell niches: insights and therapeutic opportunities. Cell Stem Cell. 2015;16:254–267. doi: 10.1016/j.stem.2015.02.014
   PubMed Web of Science ®Google Scholar
• Friedenstein AJ, Petrakova KV, Kurolesova AI, et al. Heterotopic of bone marrow. Analysis of precursor cells for osteogenic and hematopoietic tissues. Transplantation. 1968;6(2):230–247. doi: 10.1097/00007890-196803000-00009
   PubMed Web of Science ®Google Scholar
• Dominici M, Le Blanc K, Mueller I, et al. Minimal criteria for defining multipotent mesenchymal stromal cells. The international society for cellular therapy position statement. Cytotherapy. 2006;8(4):315–317. doi: 10.1080/14653240600855905
   PubMed Web of Science ®Google Scholar
• Mendez-Ferrer S, Michurina TV, Ferraro F, et al. Mesenchymal and haematopoietic stem cells form a unique bone marrow niche. Nature. 2010;466(7308):829–834. doi: 10.1038/nature09262
   PubMed Web of Science ®Google Scholar
• Fortunel NO, Hatzfeld A, Hatzfeld JA. Transforming growth factor-beta: pleiotropic role in the regulation of hematopoiesis. Blood. 2000;96(6):2022–2036.
   PubMed Web of Science ®Google Scholar
• Ruscetti FW, Akel S, Bartelmez SH. Autocrine transforming growth factor-beta regulation of hematopoiesis: many outcomes that depend on the context. Oncogene. 2005;24(37):5751–5763. doi: 10.1038/sj.onc.1208921
   PubMed Web of Science ®Google Scholar
• Xu Y, Tabe Y, Jin L, et al. TGF-beta receptor kinase inhibitor LY2109761 reverses the anti-apoptotic effects of TGF-beta1 in myelo-monocytic leukaemic cells co-cultured with stromal cells. Br J Haematol. 2008;142(2):192–201. doi: 10.1111/j.1365-2141.2008.07130.x
   PubMed Web of Science ®Google Scholar
• Blobe GC, Schiemann WP, Lodish HF. Role of transforming growth factor beta in human disease. N Engl J Med. 2000;342(18):1350–1358. doi: 10.1056/NEJM200005043421807
   PubMed Web of Science ®Google Scholar
• Kim CH, Broxmeyer HE. In vitro behavior of hematopoietic progenitor cells under the influence of chemoattractants: stromal cell-derived factor-1, steel factor, and the bone marrow environment. Blood. 1998;91(1):100–110.
   PubMed Web of Science ®Google Scholar
• Zeng Z, Shi YX, Samudio IJ, et al. Targeting the leukemia microenvironment by CXCR4 inhibition overcomes resistance to kinase inhibitors and chemotherapy in AML. Blood. 2009;113(24):6215–6224. doi: 10.1182/blood-2008-05-158311
   PubMed Web of Science ®Google Scholar
• Nervi B, Ramirez P, Retting MP, et al. Chemosensitization of acute myeloid leukemia (AML) following mobilization by the CXCR4 antagonist AMD3100. Blood. 2009;113:6206–6214. doi: 10.1182/blood-2008-06-162123
   PubMed Web of Science ®Google Scholar
• Tabe Y, Shi YX, Zeng Z, et al. TGF-beta-Neutralizing antibody 1D11 enhances cytarabine-induced apoptosis in AML cells in the bone marrow microenvironment. PLoS One. 2013;8(6):e62785. doi: 10.1371/journal.pone.0062785
   PubMed Web of Science ®Google Scholar
• Buckley CD, Amft N, Bradfield PF, et al. Persistent induction of the chemokine receptor CXCR4 by TGF-beta 1 on synovial T cells contributes to their accumulation within the rheumatoid synovium. J Immunol. 2000;165(6):3423–3429. doi: 10.4049/jimmunol.165.6.3423
   PubMed Web of Science ®Google Scholar
• Katoh M. Integrative genomic analyses of CXCR4: transcriptional regulation of CXCR4 based on TGFbeta, nodal, activin signaling and POU5F1, FOXA2, FOXC2, FOXH1, SOX17, and GFI1 transcription factors. Int J Oncol. 2010;36(2):415–420.
   PubMed Web of Science ®Google Scholar
• van Gosliga D, Schepers H, Rizo A, et al. Establishing long-term cultures with self-renewing acute myeloid leukemia stem/progenitor cells. Exp Hematol. 2007;35(10):1538–1549. doi: 10.1016/j.exphem.2007.07.001
   PubMed Web of Science ®Google Scholar
• Ito S, Barrett AJ, Dutra A, et al. Long term maintenance of myeloid leukemic stem cells cultured with unrelated human mesenchymal stromal cells. Stem Cell Res. 2015;14(1):95–104. doi: 10.1016/j.scr.2014.11.007
   PubMed Web of Science ®Google Scholar
• Antonelli A, Noort WA, Jaques J. Establishing human leukemia xenograft mouse models by implanting human bone marrow-like scaffold-based niches. Blood. 2016;128(25):2949–2959. doi: 10.1182/blood-2016-05-719021.
   PubMed Web of Science ®Google Scholar
• Tavor S, Petit I, Porozov S, et al. CXCR4 regulates migration and development of human acute myelogenous leukemia stem cells in transplanted NOD/SCID mice. Cancer Res. 2004;64(8):2817–2824. doi: 10.1158/0008-5472.CAN-03-3693
   PubMed Web of Science ®Google Scholar
• Tavor S, Eisenbach M, Jacob-Hirsch J, et al. The CXCR4 antagonist AMD3100 impairs survival of human AML cells and induces their differentiation. Leukemia. 2008;22(12):2151–5158. doi: 10.1038/leu.2008.238
   PubMed Web of Science ®Google Scholar
• Zhang Y, Patel S, Abdelouahab H, et al. CXCR4 inhibitors selectively eliminate CXCR4-expressing human acute myeloid leukemia cells in NOG mouse model. Cell Death Dis. 2012;3:e396. doi: 10.1038/cddis.2012.137
   PubMed Web of Science ®Google Scholar
• Beider K, Begin M, Abraham M, et al. CXCR4 antagonist 4F-benzoyl-TN14003 inhibits leukemia and multiple myeloma tumor growth. Exp Hematol. 2011;39(3):282–292. doi: 10.1016/j.exphem.2010.11.010
   PubMed Web of Science ®Google Scholar
• Uy GL, Rettig MP, Motabi IH, et al. A phase 1/2 study of chemosensitization with the CXCR4 antagonist plerixafor in relapsed or refractory acute myeloid leukemia. Blood. 2012;119(17):3917–3924. doi: 10.1182/blood-2011-10-383406
   PubMed Web of Science ®Google Scholar
• Massague J. How cells read TGF-beta signals. Nat Rev Mol Cell Biol. 2000;1:169–178. doi: 10.1038/35043051
   PubMed Web of Science ®Google Scholar
• Narayan S, Thangasamy T, Balusu R. Transforming growth factor-beta receptor signaling in cancer. Front Biosci. 2005;10:1135–1145. doi: 10.2741/1606
   PubMed Web of Science ®Google Scholar
• Massague J, Gomis RR. The logic of TGFbeta signaling. FEBS Lett. 2006;580:2811–2820. doi: 10.1016/j.febslet.2006.04.033
   PubMed Web of Science ®Google Scholar
• Blank U, Karlsson S. The role of Smad signaling in hematopoiesis and translational hematology. Leukemia. 2011;25:1379–1388. doi: 10.1038/leu.2011.95
   PubMed Web of Science ®Google Scholar
• Kojima Y, Acar A, Eaton EN, et al. Autocrine TGF-beta and stromal cell-derived factor-1 (SDF-1) signaling drives the evolution of tumor-promoting mammary stromal myofibroblasts. Proc Natl Acad Sci U S A. 2010;107(46):20009–20014. doi: 10.1073/pnas.1013805107
   PubMed Web of Science ®Google Scholar
• Morris JC, Shapiro GI, Tan AR, et al. Phase I/II study of GC1008: A human anti-transforming growth factor-beta (TGFb) monoclonal antibody (MAb) in patients with advanced malignant melanoma (MM) or renal cell carcinoma (RCC). J Clin Oncol. 2008;26, abstr. 9028.
   Web of Science ®Google Scholar
• Peled A, Tavor S. Role of CXCR4 in the pathogenesis of acute myeloid leukemia. Theranostics. 2013;3(1):34–39. doi: 10.7150/thno.5150
   PubMed Web of Science ®Google Scholar